Biochemist who discovered GLP-1 named winner of 2026 Kimberly Prize Svetlana Mojsovs studies have led to 'life-changing therapies for type 2 diabetes and obesity' Mojsovs studies demonstrated that GLP-1 stimulates insulin secretion and lowers blood glucose levels, which led to the development of GLP-1 receptor agonists, including semaglutide The $250,000 prize winner will also deliver a public lecture on the Feinberg campus in Chicago Mojsovs career in the laboratory has had a profound impact on human heath globally CHICAGO --- Northwestern University Feinberg School of Medicine and the Simpson Querrey Institute for Epigenetics announced today (Oct
3 The consensus guidelines recommend consideration of GLP-1 receptor agonist therapy in selected clinical situations
Additional information Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Reduced GLP-1 in BN may result from the physiological effects of recurrent purging, altered gastric capacity, or weight-suppression-related hormonal adaptations
The GLP-1 Era: Why These Intestinal Peptides Are Reshaping Modern Medicine The implications and actions of these medications go so far beyond weight loss
establishing longitudinal monitoring frameworks to elucidate doseresponse relationships and temporal patterns
